Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 | P13945 | 1/20 | 0.41 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.41 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | CTSB | P07858 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3069823 | 0.94 | ADRB3 (0.43) | ADRB3ADRA2BADRA2CCYP3A4CTSB | |
| SCHEMBL3069819 | 0.94 | ADRB3 (0.43) | ADRB3ADRA2BADRA2CCYP3A4CTSB | |
| SCHEMBL6876944 | 0.93 | ADRB3 (0.41) | ADRB3ADRA2BADRA2CCYP3A4CTSB | |
| SCHEMBL6876232 | 0.91 | ADRB3 (0.40) | ADRB3ADRA2BADRA2CCYP3A4CTSB | |
| SCHEMBL8314727 | 0.90 | ADRB3 (0.44) | ADRB3ADRA2BADRA2CCYP3A4CTSB | |
| SCHEMBL13783730 | 0.90 | ADRB3 (0.44) | ADRB3ADRA2BADRA2CCYP3A4CTSB | |
| SCHEMBL2159021 | 0.90 | ADRB3 (0.43) | ADRB3ADRA2BADRA2CCYP3A4CTSB | |
| SCHEMBL12669942 | 0.90 | ADRB3 (0.43) | ADRB3ADRA2BADRA2CCYP3A4CTSB | |
| SCHEMBL3066039 | 0.90 | ADRB3 (0.43) | ADRB3ADRA2BADRA2CCYP3A4CTSB | |
| SCHEMBL13783722 | 0.90 | ADRB3 (0.43) | ADRB3ADRA2BADRA2CCYP3A4CTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9193740-B2 | Bismacrocyclic compounds as hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2015-11-24 | — | — | US | disclosed |
| US-20110123496-A1 | BISMACROCYCLIC COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2011-05-26 | — | — | US | disclosed |
| WO-2011049908-A2 | BISMACROKYCLIC COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2011-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110123496-A1 | BISMACROCYCLIC COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS | PRSS1, CTSC, CES1 | ADRB3 3751/4885ADRA2B 4026/4885ADRA2C 2780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.